Brief: Aptorum Group Updates On Data From The Completed Phase 1 Clinical Trial Of Sact-1

Aptorum

02/05/2022 14:40

May 2 (Reuters) - Aptorum Group Ltd  APM.O :
    * APTORUM GROUP UPDATES ON DATA FROM THE COMPLETED PHASE 1
CLINICAL TRIAL OF SACT-1, TARGETING NEUROBLASTOMA
    * APTORUM GROUP LTD - STUDY TREATMENTS WERE WELL TOLERATED
AND NO
SUBJECTS WERE DISCONTINUED FROM STUDY PARTICIPATION BECAUSE OF
ADVERSE EVENTS
    * APTORUM GROUP LTD - NO SERIOUS ADVERSE EVENTS WERE
REPORTED
DURING STUDY
    * APTORUM GROUP LTD - PHASE 1 CLINICAL DATA SUGGESTED ANY QT
INTERVAL AFTER ORAL ADMINISTRATION OF SACT-1 AT 150MG WITHIN
CLINICALLY ACCEPTABLE LIMITS

Source text for Eikon:  ID:nBw3Q61TTa 
Further company coverage:  APM.O 

 ((Reuters.Briefs@thomsonreuters.com;))